A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
A Phase IV Randomized, Multicenter, Open-Label Study to Compare the Safety, Tolerability and Efficacy of Trizivir (Abacavir 300mg, Lamivudine 150mg, and Zidovudine 300mg) BID vs Combivir (Lamivudine 150mg and Zidovudine 300mg) BID Plus Atazanavir 400mg QD in Antiretroviral Naive HIV-1 Infected Subjects Over 48 Weeks
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44340
- GSK Investigational Site
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 64460
- GSK Investigational Site
-
-
-
-
California
-
Bakersfield, California, United States, 93301
- GSK Investigational Site
-
Los Angeles, California, United States, 90069
- GSK Investigational Site
-
Oakland, California, United States, 94609
- GSK Investigational Site
-
San Francisco, California, United States, 94121
- GSK Investigational Site
-
-
Colorado
-
Fort Collins, Colorado, United States, 80528
- GSK Investigational Site
-
-
District of Columbia
-
Washington, D.C., District of Columbia, United States, 20007
- GSK Investigational Site
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33306
- GSK Investigational Site
-
Fort Lauderdale, Florida, United States, 33308
- GSK Investigational Site
-
Fort Lauderdale, Florida, United States, 33145
- GSK Investigational Site
-
Fort Myers, Florida, United States, 33901
- GSK Investigational Site
-
Miami, Florida, United States, 33136
- GSK Investigational Site
-
Miami Beach, Florida, United States, 33140
- GSK Investigational Site
-
Orlando, Florida, United States, 32804
- GSK Investigational Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30339
- GSK Investigational Site
-
Decatur, Georgia, United States, 30033
- GSK Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- GSK Investigational Site
-
-
Kansas
-
Wichita, Kansas, United States, 67214
- GSK Investigational Site
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- GSK Investigational Site
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70115
- GSK Investigational Site
-
New Orleans, Louisiana, United States, 70112
- GSK Investigational Site
-
New Orleans, Louisiana, United States, 70127-0800
- GSK Investigational Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63139
- GSK Investigational Site
-
-
New Jersey
-
East Orange, New Jersey, United States, 7017
- GSK Investigational Site
-
Hillsborough, New Jersey, United States, 08876
- GSK Investigational Site
-
Newark, New Jersey, United States, 7102
- GSK Investigational Site
-
Voorhees, New Jersey, United States, 08043
- GSK Investigational Site
-
-
New York
-
Mount Vernon, New York, United States, 10550
- GSK Investigational Site
-
Valhalla, New York, United States, 10595
- GSK Investigational Site
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28209
- GSK Investigational Site
-
Greenville, North Carolina, United States, 27858-4354
- GSK Investigational Site
-
-
Ohio
-
Akron, Ohio, United States, 44304
- GSK Investigational Site
-
-
Oregon
-
Portland, Oregon, United States, 97219
- GSK Investigational Site
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18102
- GSK Investigational Site
-
Philadelphia, Pennsylvania, United States, 19140
- GSK Investigational Site
-
West Reading, Pennsylvania, United States, 19611
- GSK Investigational Site
-
-
South Carolina
-
Columbia, South Carolina, United States, 29203
- GSK Investigational Site
-
Greenville, South Carolina, United States, 29605
- GSK Investigational Site
-
-
Texas
-
Austin, Texas, United States, 78705
- GSK Investigational Site
-
Dallas, Texas, United States, 75246
- GSK Investigational Site
-
Dallas, Texas, United States, 75208
- GSK Investigational Site
-
Harlingen, Texas, United States, 78550
- GSK Investigational Site
-
Houston, Texas, United States, 77027
- GSK Investigational Site
-
-
Virginia
-
Hampton, Virginia, United States, 23666
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Adults with documented HIV-1 infection.
- Past use of HIV drugs must have been less than 15 days.
- Plasma HIV-1 RNA between 500 and 20,000 copies/mL.
- CD4+ cell count greater than 100 cells/mm3.
- Willing/able to provide written informed consent.
Exclusion criteria:
- Have AIDS at screening.
- Pregnant or breastfeeding.
- Underlying medical conditions considered to be significant for this protocol.
- Participating in other investigational drug trials.
- In the opinion of the investigator, would be unable to complete 48 weeks of dosing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The primary endpoint was drug efficacy, measured as the proportion of study subjects who had plasma HIV-1 RNA less than 50 copies/mL at week 48 and did not meet the definition of virologic failure through this timepoint.
Time Frame: 48 Weeks
|
48 Weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
% patients with plasma HIV-1 RNA <50 and <400 copies/mL at weeks 24 & 48; Change from BL in plasma HIV-1 RNA and CD4+ measures; AEs; Time to virologic failure
Time Frame: 48 Weeks
|
48 Weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Disease Attributes
- Slow Virus Diseases
- HIV Infections
- Infections
- Communicable Diseases
- Acquired Immunodeficiency Syndrome
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Atazanavir Sulfate
- Lamivudine, zidovudine drug combination
Other Study ID Numbers
Other Study ID Numbers
- 100327
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.